Evenity (Romosozumab) Geriatric (65+) School and Activity Considerations

What Is Romosozumab and Why Is It Used in Adults Over 65?

Romosozumab is a humanized monoclonal antibody that binds and inhibits sclerostin, a glycoprotein produced by osteocytes that normally suppresses bone formation. By blocking sclerostin, romosozumab simultaneously stimulates bone-forming osteoblasts and reduces osteoclast-mediated resorption. This dual action makes it the most potent bone-building agent currently approved by the FDA for osteoporosis. [1]

Adults over 65 carry the highest lifetime fracture risk. The National Osteoporosis Foundation reports that one in two women and one in four men over 50 will experience an osteoporosis-related fracture, with incidence rising steeply after age 65. [2] Hip fractures in this age group are associated with a 20-to-30% one-year mortality rate, making aggressive early intervention medically justified.

FDA Approval and Indicated Population

The FDA approved romosozumab in April 2019 under the brand name Evenity. The approved indication covers postmenopausal women with osteoporosis at high or very high fracture risk, defined as a prior osteoporotic fracture, T-score at or below -2.5 at the hip or spine, or multiple clinical risk factors. In 2022 the FDA extended approval to men with osteoporosis at high fracture risk. [1]

For geriatric patients specifically, the 12-month treatment window is time-limited, which affects how activity programs are scheduled and how follow-up antiresorptive therapy is planned.

Mechanism Compared to Other Agents

Unlike bisphosphonates (alendronate, zoledronic acid), which work solely by suppressing resorption, romosozumab adds new bone to the skeleton before the antiresorptive phase begins. The ARCH trial (N=4,093) compared romosozumab followed by alendronate against alendronate alone. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% and clinical fractures by 27% vs. Alendronate alone (P<0.001). [3]

FRAME and ARCH Trial Data Relevant to Older Adults

FRAME Trial (N=7,180)

The key FRAME trial enrolled postmenopausal women with a mean age of 71 years and a mean lumbar spine T-score of -2.7. At 12 months, romosozumab 210 mg monthly produced a 13.3% gain in lumbar spine BMD and a 6.9% gain at the total hip vs. Placebo. New vertebral fracture risk fell 73% (P<0.001). [4]

The trial did not show a statistically significant difference in serious cardiovascular events between romosozumab and placebo at 12 months, but the comparison arm was placebo rather than an active agent. [4]

ARCH Trial (N=4,093) and the Cardiovascular Signal

ARCH compared romosozumab-to-alendronate against alendronate-to-alendronate in women with a prior vertebral fracture. Cardiovascular events, specifically cardiac ischemic events and cerebrovascular events, occurred in 2.5% of the romosozumab group vs. 1.9% of the alendronate group, a difference that generated the current black-box warning. [3]

This signal is especially relevant in geriatric patients, who carry baseline cardiovascular comorbidities at much higher rates than younger cohorts. The FDA label states romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. [1]

What the Data Mean for Prescribing Over Age 65

HealthRX clinical reviewers use a three-gate screening protocol before recommending romosozumab for any patient 65 or older:

1. Cardiovascular gate. Rule out MI or stroke within 12 months. Assess 10-year ASCVD risk using the ACC/AHA Pooled Cohort Equations. Patients with very high ASCVD risk (>20%) warrant a cardiology co-sign before initiating treatment.
2. Fracture-risk gate. Confirm FRAX 10-year hip fracture probability >3% or major osteoporotic fracture probability >20%, per National Osteoporosis Foundation thresholds, or document a prior fragility fracture. [2]
3. Sequential-therapy gate. Confirm patient can adhere to antiresorptive therapy for at least 12 months after the romosozumab course ends. Gains achieved during the anabolic window are largely lost within 12 months if no antiresorptive follows. [5]

Physical Activity During Romosozumab Treatment

Weight-bearing and muscle-strengthening exercise are not just permitted during romosozumab therapy. They are specifically recommended in the 2020 American College of Rheumatology osteoporosis guidelines, which state that physical activity "reduces fracture risk independent of pharmacologic therapy." [6] Romosozumab builds bone mass; exercise teaches the musculoskeletal system to use that mass safely.

Why Exercise Complements Sclerostin Inhibition

Mechanical loading on bone suppresses sclerostin locally, which is essentially the same pathway romosozumab targets pharmacologically. A 2019 study in the Journal of Bone and Mineral Research showed that resistance exercise in postmenopausal women reduced serum sclerostin by 8.4% after 16 weeks. [7] Combining mechanical loading with a drug that systemically blocks sclerostin may produce additive effects on periosteal bone formation, though a head-to-head RCT in the geriatric romosozumab population has not yet been published.

Recommended Activity Types

The following categories are appropriate for most geriatric patients on romosozumab, absent specific contraindications:

• Weight-bearing aerobic exercise. Walking 30 minutes five days per week, stair climbing, low-impact aerobics, and dancing all load the femoral neck and lumbar spine, the two sites most clinically tracked during treatment.
• Progressive resistance training. Two to three sessions weekly targeting the hip extensors, quadriceps, and spinal extensors. The LIFTMOR trial (N=101, mean age 65) showed that high-intensity resistance and impact training increased femoral neck BMD by 0.16% compared to a -1.22% loss in the low-intensity control group over 8 months. [8]
• Balance and proprioception training. Tai chi, single-leg stance drills, and balance-board work reduce fall incidence. A Cochrane review of 59 trials (N=12,519) found that balance and functional exercise programs reduced fall rate by 24% (rate ratio 0.76, 95% CI 0.70-0.83). [9]

Activity Types Requiring Individual Risk Assessment

Some activities carry elevated fall or collision risk that deserves case-by-case evaluation rather than blanket restriction:

• Cycling on roads or trails (collision and fall risk from external hazards)
• Swimming and aquatic exercise (low bone-loading benefit but acceptable for cardiac or joint comorbidities)
• Contact sports or competitive racquet sports (fracture risk from falls or impact)
• High-altitude hiking or skiing (balance demands and emergency-access limitations)

The goal is not restriction but informed choice. A patient whose T-score has improved from -3.1 to -2.4 after six months of romosozumab may safely resume activities they avoided when their bone was more fragile, provided balance and strength training accompany the return.

Fall Prevention as a Core Clinical Activity During Treatment

Romosozumab improves bone quality, but bone quality alone does not prevent falls. Falls are the proximate cause of over 95% of hip fractures in older adults. [10] A treatment plan for any geriatric patient on romosozumab must address fall risk as vigorously as it addresses bone density.

Formal Fall-Risk Screening

The CDC STEADI (Stopping Elderly Accidents, Deaths, and Injuries) initiative recommends screening all adults 65 and older for fall risk at every clinical encounter using the Three-Key Questions screen, the Timed Up and Go (TUG) test, or the 30-Second Chair Stand test. [10] A TUG time of 12 seconds or longer identifies patients at elevated fall risk who should be referred for supervised balance training before advancing to any high-impact exercise.

Multifactorial Interventions That Reduce Falls

The USPSTF recommends exercise interventions for community-dwelling adults 65 and older who are at increased risk of falls (Grade B recommendation). [11] For patients on romosozumab, this Grade B recommendation effectively makes a supervised exercise referral the standard of care rather than an optional add-on.

Polypharmacy review deserves attention. Benzodiazepines, sedating antihistamines, antihypertensives causing orthostatic hypotension, and certain antidepressants all increase fall risk. The American Geriatrics Society Beers Criteria identify specific drug classes to avoid or dose-reduce in older adults. [12] Reviewing the full medication list at the time of romosozumab initiation catches drug-fall interactions that otherwise go unaddressed.

Home Environment Modification

A patient receiving monthly Evenity injections over a 12-month course has 12 scheduled touch-points with the healthcare system. Each visit is an opportunity to confirm adherence to home safety measures: removing loose rugs, installing grab bars in the bathroom, ensuring adequate stair lighting, and checking footwear quality. These low-cost interventions have documented efficacy in reducing fall-related injury. [10]

Scheduling the 12-Month Romosozumab Course Around Life Activities

Injection Timing and Activity Scheduling

Romosozumab is administered as two simultaneous subcutaneous injections of 105 mg each, given on the same day once monthly, for 12 consecutive months. Most patients receive injections at a clinic or infusion center, though self-administration at home is possible after training. [1]

Injection-site reactions (bruising, swelling, local pain) affect approximately 4.4% of patients in clinical trials. These reactions typically resolve within a few days and rarely interfere with physical activity schedules. Patients enrolled in exercise classes should be counseled to schedule their injection day at least 24 hours before a class that involves vigorous upper-body work, simply for comfort.

Coordinating With Community Exercise Programs

Many geriatric patients access exercise programming through:

• SilverSneakers or Silver&Fit fitness benefit programs available through Medicare Advantage plans
• Hospital-based cardiac or pulmonary rehabilitation programs (for patients with comorbid CV or respiratory disease)
• YMCA or senior center group fitness classes, including water aerobics and chair yoga
• Physical therapy (covered under Medicare Part B for medically indicated functional deficits)

None of these programs contraindicate romosozumab. The treating physician should provide a brief note to program instructors confirming that weight-bearing and resistance exercise are medically encouraged, that the patient is being treated for osteoporosis, and that sudden severe back or hip pain during exercise should prompt immediate evaluation.

School and Continuing-Education Settings

Some adults 65 and older attend community college, university continuing-education programs, or vocational training. The drug presents no special considerations for academic participation. Cognitive function is not affected by romosozumab. Injection appointments require a clinic visit of roughly 20 to 30 minutes and can be scheduled around class timetables.

Patients should carry identification noting their romosozumab treatment, particularly if they participate in any physical education, lab, or workshop course where a fall could occur. Prompt reporting of any musculoskeletal pain to their provider is standard safety guidance for all patients on bone-modifying therapy.

Cardiovascular Monitoring During the 12-Month Course

The black-box warning added to romosozumab labeling after the ARCH trial data requires ongoing vigilance, not just a one-time pre-treatment screen.

What to Monitor

Blood pressure should be assessed at every monthly injection visit. Symptom review for chest pain, dyspnea on exertion, new-onset palpitations, or signs of transient ischemic attack should be documented. There is no specific cardiac biomarker monitoring required in the FDA label, but clinicians managing patients with known coronary artery disease or prior stroke often obtain an annual lipid panel and ECG as standard geriatric care.

If a patient experiences an MI or stroke during the 12-month course, romosozumab must be discontinued. The American Heart Association's 2020 scientific statement on osteoporosis and cardiovascular disease notes that bisphosphonates carry a more favorable cardiovascular safety profile for patients at high CV risk and may be preferred in that subgroup. [13]

Sequential Therapy After Month 12

Stopping romosozumab without following it with an antiresorptive leads to rapid BMD loss. The FDA label and the Endocrine Society's 2019 clinical practice guideline both specify that an antiresorptive agent (denosumab 60 mg every 6 months or an oral or IV bisphosphonate) must follow the 12-month romosozumab course to maintain skeletal gains. [1, 5]

For geriatric patients with poor oral tolerability or adherence concerns, zoledronic acid 5 mg IV once yearly is often preferred, since a single annual infusion avoids the daily or weekly pill burden of oral bisphosphonates. The FRAME extension study showed that transitioning from romosozumab to denosumab produced a further 3.8% lumbar spine BMD increase at 12 months post-transition, compared to a 2.7% loss in patients who switched to placebo. [4]

Practical Prescribing Considerations for the Geriatric Patient

Calcium, Vitamin D, and Nutritional Support

Romosozumab increases bone formation rapidly, which generates a transient increase in calcium demand. Supplemental calcium 1,000 mg daily (in divided doses for absorption) and vitamin D 800 to 1,000 IU daily are required throughout the 12-month course. [1] Inadequate calcium intake during anabolic therapy can cause secondary hyperparathyroidism, which would blunt the BMD response.

Geriatric patients are at particular risk for vitamin D insufficiency. A serum 25-hydroxyvitamin D level below 20 ng/mL (50 nmol/L) should be corrected before initiating romosozumab. CDC data indicate that approximately 28.9% of U.S. Adults aged 65 and older have vitamin D insufficiency based on serum levels below 20 ng/mL. [14]

Renal Function Considerations

Romosozumab is not recommended in patients with severe renal impairment (estimated GFR <30 mL/min/1.73 m²) or end-stage renal disease, as clinical data in this population are limited. [1] Since CKD prevalence rises to over 38% in adults 65 and older in the U.S., checking a basic metabolic panel with eGFR before prescribing is standard practice. [14]

Hypocalcemia Risk

Pre-existing hypocalcemia must be corrected before starting romosozumab. The FDA label lists uncorrected hypocalcemia as a contraindication. Serum calcium should be checked at baseline and at least once during the treatment course, particularly in patients on diuretics or proton pump inhibitors that impair calcium absorption.

Monitoring Bone Mineral Density During and After Treatment

Dual-energy X-ray absorptiometry (DXA) should be performed at baseline before starting romosozumab and repeated at 12 months (end of treatment) to document the anabolic response. Follow-up DXA at 24 months (12 months into antiresorptive therapy) confirms that sequential treatment is sustaining the gains.

The International Society for Clinical Densitometry specifies a minimum significant change of 3-6% at the lumbar spine and 3-4% at the total hip for the same DXA machine and technologist to exceed measurement error. [15] A clinically meaningful BMD response to romosozumab at the lumbar spine, averaging 13% in FRAME, substantially exceeds this threshold and provides objective reassurance for both patient and prescriber.

T-score improvement does not fully capture fracture-risk reduction. FRAX recalculation after 12 months of treatment, incorporating the new BMD values, gives a more complete picture of residual fracture risk and guides decisions about which antiresorptive to use and for how long. [2]